Concepedia
Statistics
Publications
23
Citations
7.9K
H-Index
20
Active since
1997
Affiliations
Vanderbilt University(Current)
Exelixis (United States)
Aptose Biosciences (United States)
University of California, San Francisco
Stanford University
F. Michael Yakes is an author at Vanderbilt University specializing in oncology, molecular oncology, and medicine.
Publications per year
1997–2017
Mitochondrial DNA damage is more extensive and persists longer than nuclear DNA damage in human cells following oxidative stress
F. Michael Yakes, Bennett Van Houten · Proceedings of the National Academy of Sciences · 1997 · 1.8K citations
Life Sciences, Cell Biology, Molecular Biology +15
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
F. Michael Yakes, Jason Chen, Jenny Tan et al. · Molecular Cancer Therapeutics · 2011 · 1.3K citations · Full text
Medicine, Oncology, Pharmacology +17
PKB/Akt mediates cell-cycle progression by phosphorylation of p27Kip1 at threonine 157 and modulation of its cellular localization
Incheol Shin, F. Michael Yakes, Federico Rojo et al. · Nature Medicine · 2002 · 786 citations
Life Sciences, Cell Biology, Molecular Biology +16
Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.
F. Michael Yakes, Wichai Chinratanalab, Christoph A. Ritter et al. · PubMed · 2002 · 617 citations
Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Stacy L. Moulder, F. Michael Yakes, Senthil K. Muthuswamy et al. · PubMed · 2001 · 549 citations
Medicine, Oncology, Pharmacology +16
1–5 of 23